Drug Trial Radar · NCT06144060
A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
126
Planned (sponsor's estimate)
Start
Dec 2023
Primary completion
Jun 2024
Study completion Jul 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
Conditions
- Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Interventions
HRS -8427Drug
The dose and frequency of administration were adjusted according to the eGFR.
Imipenem and Cilastatin SodiumDrug
The dose and frequency of administration were adjusted according to the eGFR .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.